| abstract |
This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents. In a principal embodiment, the pentofuranonucleoside is of Formula (I): (see formula I) wherein R, R1, R1', R2, R2', R3, R3', X and Base are as defined herein. |